focus -WSS

focus

author：explore 2025-09-06 03:40:46 - browse：8863

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Congress must protect the remaining independent doctors

WSS

Doctors on social media are being harassed and cyberbullied

Food makers tried to stack nutrition panel with preferred experts

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Generate Biomedicines machine learning biotech raises $273M

hotspot

focus

explore

Medicare details structure of new drug price negotiation program

AMAs digital advisors table RPM coding reform proposal, again

Heart attack and stroke risk calculators need revising

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Congress must protect the remaining independent doctors

Tori Bowie and the unacceptable rates of Black maternal death

New Covid vaccine is recommended for everyone 6 months or older

Peter Hotez and the public health issue of online harassment

Bernie Sanders gets little from pharma CEOs on drug prices

knowledge

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Artificial intelligence use in health care faces greater scrutiny in 2024

How housing is health care on Long Island

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Too many hospitalized Covid

Wikipedia

hotspot

leisure time

Wikipedia